EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia

Madison E Stellfox iD, Carolyn Fernandes, Ryan K Shields iD, Ghady Haidar iD, Kailey Hughes Kramer, Emily Dembinski, Mihnea R Mangalea, Garima Arya, Gregory S Canfield, Breck A Duerkop iD, Daria Van Tyne iD

mBio · 13.03.2024 · 15 (3)

DOI: 10.1128/mbio.03396-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 13.03.2024. Verfasst von Madison E Stellfox und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Enterococcus faecium, Bacteriophages, Bacteremia, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enterococcus faecium is a member of the human gastrointestinal (GI) microbiota but can also cause invasive infections, especially in immunocompromised hosts. Enterococci display intrinsic resistance to many antibiotics, and most clinical E. faecium isolates have acquired vancomycin resistance, leaving clinicians with a limited repertoire of effective antibiotics. As such, vancomycin-resistant E. faecium (VREfm) has become an increasingly difficult to treat nosocomial pathogen that is often associated with treatment failure and recurrent infections. We followed a patient with recurrent E. faecium bloodstream infections (BSIs) of increasing severity, which ultimately became unresponsive to antibiotic combination therapy over the course of 7 years. Whole-genome sequencing (WGS) showed that the patient was colonized with closely related E. faecium strains for at least 2 years and that invasive isolates likely emerged from a large E. faecium population in the patient’s gastrointestinal (GI) tract. The addition of bacteriophage (phage) therapy to the patient’s antimicrobial regimen was associated with several months of clinical improvement and reduced intestinal burden of VRE and E. faecium. In vitro analysis showed that antibiotic and phage combination therapy improved bacterial growth suppression compared to therapy with either alone. Eventual E. faecium BSI recurrence was not associated with the development of antibiotic or phage resistance in post-treatment isolates. However, an anti-phage-neutralizing antibody response occurred that coincided with an increased relative abundance of VRE in the GI tract, both of which may have contributed to clinical failure. Taken together, these findings highlight the potential utility and limitations of phage therapy to treat antibiotic-resistant enterococcal infections. IMPORTANCE Phage therapy is an emerging therapeutic approach for treating bacterial infections that do not respond to traditional antibiotics. The addition of phage therapy to systemic antibiotics to treat a patient with recurrent E. faecium infections that were non-responsive to antibiotics alone resulted in fewer hospitalizations and improved the patient's quality of life. Combination phage and antibiotic therapy reduced E. faecium and VRE abundance in the patient's stool. Eventually, an anti-phage antibody response emerged that was able to neutralize phage activity, which may have limited clinical efficacy. This study demonstrates the potential of phages as an additional option in the antimicrobial toolbox for treating invasive enterococcal infections and highlights the need for further investigation to ensure phage therapy can be deployed for maximum clinical benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterococcus faeciumBacteriophagesBacteremiaGram-Positive Bacterial InfectionsVancomycin-Resistant EnterococciHumansAnti-Bacterial AgentsQuality of LifeEnterococcusMicrobial Sensitivity Tests

Stichwörter der Autor:innen

bacteriophage therapyphage-neutralizing antibodiesvancomycin-resistant Enterococcus faecium

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.

ORCID-Profile: Madison E Stellfox, Ryan K Shields, Ghady Haidar, Breck A Duerkop, Daria Van Tyne

Förderung

  • NIAID NIH HHS
  • NIAMS NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Stellfox, M. E., Fernandes, C., Shields, R. K., Haidar, G., Hughes Kramer, K., Dembinski, E., Mangalea, M. R., Arya, G., Canfield, G. S., Duerkop, B. A., & Van Tyne, D. (2024). Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia. mBio, 15(3). https://doi.org/10.1128/mbio.03396-23

Vancouver

Stellfox ME, Fernandes C, Shields RK, Haidar G, Hughes Kramer K, Dembinski E, et al. Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia. mBio. 2024;15(3). doi:10.1128/mbio.03396-23

BibTeX
@article{Stellfox2024,
  author = {Stellfox, Madison E and Fernandes, Carolyn and Shields, Ryan K and Haidar, Ghady and Hughes Kramer, Kailey and Dembinski, Emily and Mangalea, Mihnea R and Arya, Garima and Canfield, Gregory S and Duerkop, Breck A and Van Tyne, Daria},
  title = {Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia},
  journal = {mBio},
  year = {2024},
  volume = {15},
  number = {3},
  doi = {10.1128/mbio.03396-23}
}
Kostenlos starten →